MLN2704 effectively inhibits tumor growth in models of human prostate cancer expressing PSMA.

被引：0
|
作者：
Wen, SH [1 ]
Silva, M [1 ]
Riordan, W [1 ]
Shi, J [1 ]
Young, E [1 ]
Meyers, M [1 ]
Green, M [1 ]
Milton, M [1 ]
Chandra, S [1 ]
Worland, PJ [1 ]
Henry, MD [1 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6187S / 6187S
页数：1
相关论文
共 50 条
  • [1] Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC).
    Galsky, MD
    Eisenberger, M
    Moore-Cooper, S
    Kelly, WK
    Slovin, S
    Morales, A
    Curley, T
    Delacruz, A
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 404S - 404S
  • [2] Preclinical efficacy evaluation of MLN2704: A chemotherapeutic-monoclonal antibody conjugate targeting prostate-specific membrane antigen (PSMA)
    Henry, M
    Myers, M
    Wen, S
    Rabino, C
    Im, J
    Tang, Y
    Worland, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S150 - S150
  • [3] Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC).
    Milowsky, M. I.
    Galsky, M.
    George, D. J.
    Lewin, J. M.
    Rozario, C. P.
    Marshall, T.
    Chang, M.
    Nanus, D. M.
    Webb, I. J.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 217S - 217S
  • [4] Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Milowsky, MI
    Galsky, M
    Lewin, J
    Rozario, CP
    Owens, L
    Marshall, T
    Nanus, D
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 406S - 406S
  • [5] Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Galsky, Matthew D.
    Eisenberger, Mario
    Moore-Cooper, Sandra
    Kelly, W. Kevin
    Slovin, Susan F.
    DeLaCruz, Anthony
    Lee, Yih
    Webb, Iain J.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2147 - 2154
  • [6] A novel fully human antibody targeting extracellular domain of PSMA inhibits tumor growth in prostate cancer
    Wu, J.
    Han, D.
    Shi, S.
    Yang, A. -G
    Qin, W.
    Wen, W.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1740 - 1741
  • [7] A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer
    Wu, Jieheng
    Han, Donghui
    Shi, Shengjia
    Zhang, Qiang
    Zheng, Guoxu
    Wei, Ming
    Han, Yueheng
    Li, Guodong
    Yang, Fa
    Jiao, Dian
    Xie, Pin
    Zhang, Lingling
    Yang, An-Gang
    Zhao, Aizhi
    Qin, Weijun
    Wen, Weihong
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (07) : 1289 - 1301
  • [8] Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer
    Fontana, Luigi
    Adelaiye, Remi M.
    Rastelli, Antonella L.
    Miles, Kiersten Marie
    Ciamporcero, Eric
    Longo, Valter D.
    Nguyen, Holly
    Vessella, Robert
    Pili, Roberto
    ONCOTARGET, 2013, 4 (12) : 2451 - 2461
  • [9] Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy
    Jin, FS
    Xie, ZH
    Kuo, CJ
    Chung, LWK
    Hsieh, CL
    CANCER GENE THERAPY, 2005, 12 (03) : 257 - 267
  • [10] Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy
    Fengshuo Jin
    Zhihui Xie
    Calvin J Kuo
    Leland W K Chung
    Chia-Ling Hsieh
    Cancer Gene Therapy, 2005, 12 : 257 - 267
12345